Human tumor antigens recognized by T cells.
The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.
Robbins
P F
PF
Surgery Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD 20892-1502, USA. pfr@helix.nih.gov
Kawakami
Y
Y
D000595:Amino Acid Sequence; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics; D019496:Cancer Vaccines / Q000494:pharmacology; D002986:Clinical Trials as Topic; D000939:Epitopes / Q000235:genetics; D006801:Humans; D007108:Immune Tolerance; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes